Ncardia
Stefan Braam serves as President and CTO at Ncardia since August 2017 and also holds the position of Chief Executive Officer at Cellistic since April 2022. Previously, Stefan was the Chief Executive Officer and Chief Scientific Officer at Pluriomics from October 2010 to August 2017, where responsibilities included technology development, R&D, and business strategy. Stefan was involved as a Global Shaper from October 2011 to June 2015 and worked as a Research Scientist at LUMC from April 2010 to February 2012, contributing to the establishment of Pluriomics. Educational qualifications include a PhD in Stem Cell Research from LUMC and Hubrecht Institute, an MSc in Developmental Biology and Biomedical Genetics from Utrecht University, and a BSc in Biomedical Lab Research from Saxion University of Applied Sciences.
Ncardia
Ncardia is a drug discovery company and expert in human iPSC technology. We operate worldwide with facilities, offices and staff throughout Europe and North America. We work with biopharmaceutical companies in drug discovery worldwide, to leverage the power of stem cell technologies in the development of novel therapies of multiple modalities at any stage of development. Over the past 10 years, we have built the expertise and infrastructure required to differentiate, manufacture and characterize high-quality iPSC-derived cell and disease models. We can facilitate the process of disease modeling and high-throughput screening to accelerate drug discovery. We listen to our customer’s project plans, questions and challenges, and co-develop human iPSC-based solutions that fit their specifications. Explore our website to learn more www.ncardia.com.